Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06311474 · ClinicalTrials.gov registry record · NA

Remote Assessment and Intervention for Behavior Problems in Kids With TSC

A NA study, sponsored by University of California, Los Angeles.

Completed
Registry status
NA
Development phase
101
Enrollment target

NCT06311474 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 101 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06311474, a NA study, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
NA
Development phase
101 participants
Enrollment target

Study Summary

The RAINBOW study is a fully remote study focused on understanding and treating behavior problems in young children with tuberous sclerosis complex (TSC). The first goal is to enroll a group of 100 children with TSC between the ages of 3 and 6 years old, with and without problem behaviors, to learn about how best to measure behavioral challenges in TSC and how common these behaviors are during this age period. All families will get feedback from the clinical assessments collected. Eligible children who are experiencing behavior problems will be invited to enroll in a pilot clinical trial of internet-based Parent-Child Interaction Therapy (or PCIT), which is meant to help parents better manage their children's challenging behaviors. Adaptations to PCIT are incorporated to suit the needs of TSC children and families. Some participants will be randomly selected to receive the intervention immediately and others after a 6-month delay, but all families will receive the same intervention. Intervention sessions occur on a weekly basis for up to 20 weeks. Follow-up assessments, which include play interactions, parent interviews, and questionnaires occur about 3 and 6 months after the first visit. The delayed treatment group has an extra brief assessment about 12 months from the initial visit. This study will increase what is known about the types of behavior problems that come up during preschool age in TSC and how best to help children and families with TSC who are experiencing these problems.

Interventions

  • BEHAVIORAL Parent-Child Interaction Therapy (PCIT)

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2022-08-01
Est. Completion 2025-12-04
Phase NA

What the Registry Record Tells You About NCT06311474

The ClinicalTrials.gov registry entry for NCT06311474 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Parent-Child Interaction Therapy (PCIT) is the first listed.

NCT06311474 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06311474 about?

NCT06311474 is a clinical study titled "Remote Assessment and Intervention for Behavior Problems in Kids With TSC". The RAINBOW study is a fully remote study focused on understanding and treating behavior problems in young children with tuberous sclerosis complex (TSC). The first goal is to enroll a group of 100 children with TSC between the ages of 3 and 6 years old, with and without problem behaviors, to learn ...

What is the current status of trial NCT06311474?

This trial is currently completed. It is a NA study. The enrollment target is 101 participants. The study started on 2022-08-01. Estimated completion is 2025-12-04.

What interventions are being tested in trial NCT06311474?

The interventions under investigation include: Parent-Child Interaction Therapy (PCIT) (BEHAVIORAL).

Who is sponsoring clinical trial NCT06311474?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.